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Abstract: Euphorbia genus (Euphorbiaceae family), which is the third largest genus of angiosperm
plants comprising ca. 2000 recognized species, is used all over the world in traditional medicine,
especially in the traditional Chinese medicine. Members of this taxa are promptly recognizable by
their specialized inflorescences and latex. In this review, an overview of Euphorbia-derived natural
products such as essential oils, extracts, and pure compounds, active in a broad range of biological
activities, and with potential usages in health maintenance, is described. The chemical composition
of essential oils from Euphorbia species revealed the presence of more than 80 phytochemicals,
mainly oxygenated sesquiterpenes and sesquiterpenes hydrocarbons, while Euphorbia extracts contain
secondary metabolites such as sesquiterpenes, diterpenes, sterols, flavonoids, and other polyphenols.
The extracts and secondary metabolites from Euphorbia plants may act as active principles of medicines
for the treatment of many human ailments, mainly inflammation, cancer, and microbial infections.
Besides, Euphorbia-derived products have great potential as a source of bioactive extracts and pure
compounds, which can be used to promote longevity with more health.
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1. Introduction
The genus Euphorbia (Euphorbiaceae) is the third major genus of flowering plants, with 1836
accepted species [1,2], subdivided into many subgenera and sections. This genus has a worldwide
distribution and can be found in all temperate and tropical regions. Also, this group of plants
is characterized by an extraordinary variety of forms, from small ephemerals to several forms of
herbaceous annuals or perennials, big shrubs, small trees, cushion-forming subshrubs, and cactus-like
succulents [3]. From the 243 Euphorbia species assessed by the IUCN Red List of Threatened species, 170
(70%) are threatened with extinction (categories vulnerable, endangered, and critically endangered) [4].
More than 5% of species of Euphorbia are used in traditional medicine, mainly as emetic and
purgative agents, to treat digestive and respiratory disorders, skin and inflammatory conditions,
migraine, intestinal parasites and gonorrhoea, and as wart cures [5–9]. The usable parts of the Euphorbia
species include roots, seeds, latex, wood, barks, leaves, and whole plants [5–9]. A brief overview of
traditional medicine applications of Euphorbia is described in Section 2.
Euphorbia species have these curative properties due to the presence of various phytochemicals,
which constitute the secondary metabolites of these plants [1,10–17]. They belong mainly to the
terpenoids, flavonoids and polyphenols classes which also exhibit a great variety of biological effects
such as cytotoxic, mammalian mitochondrial respiratory chain inhibition, HIV-1 and bacterial infection
inhibition, anti-inflammatory, multidrug resistance modulators [13,18–23]. In fact, there is a good
attention in Euphorbia-derived metabolites mainly because of the diterpene ingenol mebutate identified
on E. peplus L. (as well as on E. lathyris L., E. nivulia Buch.-Ham., E. esula L., E. antiquorum L., E. serpens
Kunth, and E. fischeriana Steud.), and is the active ingredient of Picato®medicine used in topical therapy
against the precancerous skin condition actinic keratosis [24–26]. However, some Euphorbia compounds
are toxic, resulting from an evolutionary strategy of plant defence against predators (e.g., herbivores),
compounds that have a caustic and irritating effect to the skin and promote tumours [10,27].
Euphorbia plants are easily distinguishable by their toxic and highly skin irritant milky latex and
particular inflorescences, designated as cyathia [28,29], and are widely used as ornamental plants, such
as E. milii Des Moul., E. tirucalli L., and E. lactea Roxb [30]. The latex is the most valuable product
obtained from Euphorbia species despite being toxic, it contains several biologically active natural
compounds, such as triterpenoids [31]. Besides, latex is used in commercially valuable products like
paints and natural rubber (intisy rubber obtained from E. intisy Drake) [30,32].
Secondary metabolites contained in Euphorbia plants also potentiate their use for food preservation.
According to Toro-Vazquez et al. [33], candelilla wax obtained from the leaves of some species of
Euphorbia found in Northern Mexico and the Southwest of the United States was recognized by the
Food and Drug Administration (FDA) as a food additive with gelling properties, forming oleo-gels
together with vegetable oils. According to EU regulations, candelilla wax is assigned by E902 additive
code, and it is also an allowed glazing agent, applied on the surface of confectionery, nuts, wafers,
coffee grains, dietary supplements, and fresh fruit [34].
Taking into account the great interest of the Euphorbia plants, we aim to touch on the chemical
composition of essential oils, the therapeutic potential, in vitro, in vivo, and clinical trials of Euphorbia
extracts and the pure compounds. We adopt the Latin binomial taxonomic name of the Euphorbia
species considered by the Plant List database. When it does not match with the taxonomic name
indicated in the bibliographic reference, the synonym will be shown in parentheses.
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2. Traditional Medicine Uses of Euphorbia Plants
The Euphorbia genus is well-known to involve several plants used in folk medicine in different parts
of the world, especially in traditional Chinese medicine [5,7,9]. Moreover, a recent study discriminated
the global geographical distribution regarding uses of Euphorbia plants in traditional medicine [6]. In
this regard, three particular uses were most often detected, such as (1) treatments of digestive system
disorders (very globally frequent excepting Australasia); (2) as remedies for infections/infestations
(mainly in Southern Africa and America, Pacific, Asia-tropical, and Asia-temperate); and (3) for treating
skin/subcutaneous cellular tissue disorders (particularly in Australasia, Europe, Asia, and Northern
America). On the other hand, within the 33 species with citations in folk practices worldwide, the three
most-referenced plants used as traditional medicines were E. hirta L., E. thymifolia L., and E. lathyris [6].
Euphorbia hirta whole plant has been employed in Burundi, China, Philippines, and Nigeria to
manage diarrhoea [35–38], while E. hirta decoction is used in Vietnam, India, and Mozambique to treat
dysentery [39–41] and to treat bronchitis/asthma/coughs in Nepal, Australia, the South Western United
States, and Hawaii [6,39,42]. Additionally, the latex from E. hirta is also applied to treat skin diseases
and fever mostly in Asia [6] and to treat gonorrhoea in Malaysia [43] and other conditions such as
malaria, candidiasis, and ringworm infections [6]. Populations aroundthe Vellore District of Tamil
Nadu, India, use decoction of the E. hirta whole plant to treat poisonous snakebites (topically and
orally administration) [44].
Despite the registered abortifacient properties of E. thymifolia decoctions in Chile, its latex or
leaf decoctions have been recorded as lactation stimulants in different continents [45]. In the case of
E. lathyris, emetic and purgative actions have been described in Europe as well as its seeds used to treat
snakebites, ascites, schistosomiasis, and hydropsy [38,46].
Euphorbia maculata L. in Northern America is used for the treatment of corneal opacities and
warts [47], while in China, it is used to treat blood disorders (e.g., haematuria, haemoptysis, epistaxis,
and hemafecia), carbuncles, and wounds [38]. Euphorbia denticulata Lam. and E. macrocarpa Boiss. &
Buhse are also used for wound healing in Turkey [48], and a similar use is reported in Ethiopia for
E. heterophylla L. and E. prostrata Aiton [49].
The decoction, unguent, or hot steam of other Euphorbia species are used on inflammation
conditions, such as E. corollata L. (for dropsy), E. marginata Pursh, and E. antiquorum (for swellings) [6].
Similarly, E. antiquorum is utilized in Vietnam to alleviate toothache events [41] as well as for treating
cutaneous dropsy, cutaneous infections, cancer, and liver ailment [50]. E. tirucalli L. and E. ingens E.Mey.
ex Boiss. like E. lathyris, can be used as an emetic against snakebites [39,51]. A recent review has been
published showing that E. tirucalli (whole plant and its parts individually separated) has some records
in South America, India, the Middle East, and Africa regarding beneficial effects on leprosy, syphilis,
cancer, asthma, and intestinal parasites [51]. The same research group [52] also published a review
where they report the various applications in traditional medicine of E. neriifolia L. Its latex is used as a
carminative and expectorant, as well as in the treatment of tumours, abdominal and skin problems,
leprosy, asthma, and kidney stones, while the roots are used in the treatment of scorpion stings and
snake bites. The leaves can also be used as carminative and in the treatment of pain, inflammation,
bronchial infections and lack of appetite [52]. Euphorbia helioscopia L. is used in the traditional Chinese
medicine in situations of bacillary dysentery, osteomyelitis, and malaria [53]. In Uyghur medicine,
China, E. resinifera O.Berg is recurrently employed to suppress tuberculosis, toothache, and chronic
pain [54], while E. fischeriana have been used as a remedy for cancer, ascites, and oedema [55], and
E. granulata Forssk. is utilized against intestine worms, oedema, cough, blood impurities, and renal
diseases [56,57].
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However, some Euphorbia plants, especially their latex or milky sap (e.g., E. hirta, E. helioscopia,
E. royleana Boiss. among others), are considered as irritating materials for skin, mouth, and throat,
causing burning sensation, acute inflammation (even blisters), and nausea [58]. In veterinary medicine,
E. milii Des Moul. and E. nivulia is used to treat diarrhoea and wounds in livestock, respectively, but
other Euphorbia species can produce irritations [6].
3. Euphorbia Plants: Essential Oil Composition and Activities
Researchers from various countries worldwide have studied the chemical composition of essential
oils (EOs) from different Euphorbia species. An overview of their most abundant components (the
content higher than 5%) along with the most relevant biological activities to health maintenance (when
available, and when the biological activity of a positive standard compound was also presented) is
given in Table 1. The chemical structure of the major constituents of EOs from Euphorbia species whose
content is higher than 25% is depicted in Figure 1.Biomolecules 2019, 9, 337 7 of 20 
 
Figure 1. Chemical structures of the constituents of Euphorbia essential oil, each one with a content 
exceeding 25%. 
The Table 1 data show that EOs were obtained mainly from aerial parts (39%) and 
inflorescences (29%), in addition to leaves (18%), roots (11%), and stems (3%), by using basically two 
extraction methods—hydro-distillation (HD) (52%) and steam distillation (SD) (45%). The oil yield 
ranged from 0.07% to 1.52% (w/v) in E. cotinifolia (syn. E. caracasana) and E. fischeriana, and from 
0.08% to 0.84% (w/w) in E. pilosa and E. densa. Microwave-assisted extraction (MAE) was reported 
only once (3%) with faster extraction time (3:1) and higher oil yield (1.2% vs. 0.7% w/v) than 
conventional techniques (MAE vs. HD) [74]. Qualitative and quantitative analyses were performed 
by gas chromatography (GC) or GC coupled to mass spectrometry (GC-MS). Samples were found to 
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From Table 1, it appears that most of the EOs of Euphorbia species studied exhibit antioxidant 
properties, especially by the radical scavenging mechanism. Note that some of them are more active 
than ascorbic acid, BHT, or BHA compounds well known for their antioxidant properties and are 
widely used in the food industry as a preservative. 
On the other hand, the data presented also show that there are many Euphorbia species whose 
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Table 1. Chemical composition and biological activities of Euphorbia essential oils.
Species Origin Raw Material Extraction Method Main Components a (%) Most RelevantBiological Activities Ref.
E. acanthothamnos Heldr.
& Sart. ex Boiss. Greece Inflorescences Steam distillation
Phytol (28.3), phytol acetate (9.3),
β-caryophyllene (7.5) not evaluated [59]
E. apios L. Greece Inflorescences Steam distillation
Germacrene D (30.0),
heptacosane (12.7),
β-caryophyllene (10.0), tricosane (6.5),
pentacosane (6.0)
not evaluated [59]
E. characias L. Greece Inflorescences Steam distillation
Nonanal (22.8), phytol (13.5),
pentacosane (8.5), heptacosane (7.4),
palmitic acid (5.7), nonacosane (5.6)
not evaluated [59]
E. cotinifolia L. (syn.
E. caracasana (Klotzsch
& Garcke) Boiss.)
Venezuela Leaves Hydro-distillation
β-Caryophyllene (39.3),
germacrene-D (21.5%), α-copaene (9.3),
α-humulene (5.2)
not evaluated [60]
E. dendroides L. Greece Inflorescences Steam distillation Heptacosane (10.5), pentacosane (6.0),4-terpineol (5.5), tricosane (5.0) not evaluated [59]
E. densa Schrenk Syria Aerial parts Hydro-distillation
1,8-Cineole (18.87), linalool (13.61),
carvacrol (13.32),
(E)-caryophyllene (10.29)
Radical scavenging activity (EC50
= 0.35 µg/mL) lower than
BHA (EC50 = 0.135 µg/mL)
[61]
E. fischeriana Steud. China Roots Steam distillation
Eudesmol (18.22),
p-menth-8-en-2-ol (9.36),
caryophyllene oxide (8.61),
selinenol (6.83)
Radical scavenging activity (IC50
= 57.2 µg/mL) similar to ascorbic
acid (IC50 = 63.1 µg/mL) but
lower than BHT (IC50 =
26.1 µg/mL)
[62]
E. fragifera Jan Italy Inflorescences Steam distillation
Carvacrol (61.55), carvon (9.22),
β-caryophyllene (5.80)/geraniol (59.65),
β-caryophyllene (9.05)
not evaluated [63]
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Table 1. Cont.
Species Origin Raw Material Extraction Method Main Components a (%) Most RelevantBiological Activities Ref.
E. gaillardotii Boiss. &
Blanche Turkey Aerial parts Hydro-distillation
Arachidic acid (32),
hexatriacontane (8.7), mint
furanone (8.4), palmitic acid (8.0),
tetratetracontane (6.2),
octadecane (5.6), α-silenene (5.2)
Anti-lipid peroxidation
activity (IC50 = 14.8 µg/mL)
similar to α-tocopherol, but
much lower radical scavenging
activity than BHT.
[64]
E. golondrina
L.C.Wheeler Cameroon Leaves Steam distillation
Caryophyllene oxide (14.16),
2-pentadecanone (13.78),
camphor (9.41), phytol (5.75)
not evaluated [65]
E. hebecarpa Boiss. Iran Aerial parts Hydro-distillation
α-Bisabolol (31.2),
cis-cadin-4-en-7-ol (20.1),
trans-piperitol (8.6),
cis-p-menth-2-en-1-ol (6.4),
trans-p-menth-2-en-1-ol (6.2)
not evaluated [66]
E. helioscopia L. Greece Inflorescences Steam distillation
Phytol (21.2), β-caryophyllene (10.0),
behenic acid methyl ester (8.1),
myristic acid methyl ester (5.5)
not evaluated [59]
E. helioscopia L. Turkey Aerial parts Hydro-distillation
β-Cubebene (19.3), palmitic acid (12.2),
caryophyllene oxide (11.7),
τ-elemene (9.3), spathulenol (9.3),
phytol (6.9), hexahydrofarnesly
acetone (5.3)
Low antioxidant and
antiacetylcholinesterase activity,
moderate butyrylcholinesterase
and similar anti-urease activity
to thiourea.
[67]
E. heterophylla L. Nigeria Leaves Hydro-distillation
3,7,12,15-Tetramethyl-2-hexadecen-1-ol
(12.30), stearic acid (11.21), oleic
acid (10.42), linoleic acid (8.97),
1,2-epoxy-cyclododecane (7.91),
13-tetradece-11-yn-1-ol (7.83),
7,10-hexadecadienal (7.62),
1,2,15,16-diepoxyhexadecane (6.37),
phytol (6.32), 2-monopalmitin (5.43)
Toxic to brine shrimp
larvae (LC50 = 21.7 µg/mL).
Radical scavenging activity
similar to ascorbic acid, lower
than BHA but higher than
α-tocopherol at 250 µg/mL.
[68]
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Table 1. Cont.
Species Origin Raw Material Extraction Method Main Components a (%) Most RelevantBiological Activities Ref.
E. heterophylla L. Nigeria Stems Hydro-distillation
Stearic acid (11.21), oleic acid (10.42),
linoleic acid (8.97),
1,2-epoxy-cyclododecane (7.91),
13-tetradece-11-yn-1-ol (7.83),
7,10-hexadecadienal (7.62),
1,2,15,16-diepoxyhexadecane (6.37),
phytol (6.32), 2-monopalmitin (5.43),
2-aminoethoxyethynediyl methyl
ester (5.40)
Very toxic to brine shrimp
larvae (LC50 = 8.94 µg/mL).
Radical scavenging activity
similar to ascorbic acid, lower
than BHA but higher than
α-tocopherol at 250 µg/mL.
[68]
E. heterophylla L. Egypt Aerial parts Hydro-distillation 1,8-Cineole (32.0), camphor (16.5),
β-elemene (5.9 )
Radical scavenging activity (IC50
325.3 µL/L) lower than ascorbic
acid (204.4 µL/L).
[69]
E. hirta L. Lagos Leaves Hydro-distillation
Phytol and its isomeric forms (34.8),
6,10,14-trimethyl-2-pentadecanone
(12.37), hexadecanal (7.63),
palmitic acid (6.26)
not evaluated [70]
E. macroclada Boiss. Turkey Aerial parts Hydro-distillation
Tetratetracontane (42.7),
hexatriacontane (12), mint
furanone (6.0)
Anti-lipid peroxidation
activity (IC50 = 14.8 µg/mL)
similar to α-tocopherol. Lower
radical scavenging activity than
BHT but higher than
E. gaillardotii essential oil.
[64]
E. macrorrhiza C.A.Mey.
ex Ledeb. China Aerial parts Hydro-distillation
Acorenone B (16.72),
(+)-cycloisosativene (14.94),
3β-hydroxy-5α-androstane (10.62),
β-cedrene (8.40), copaene (7.37),
palmitic acid (5.68)
Cytotoxic activity against Caco-2
cell line (IC50 = 78.32 µg/mL),
antibacterial activity against
Staphyloccocus aureus (MIC =
5.6 µg/mL) but lower than
ampicillin (MIC = 0.25 µg/mL)
[71]
Biomolecules 2019, 9, 337 8 of 22
Table 1. Cont.
Species Origin Raw Material Extraction Method Main Components a (%) Most RelevantBiological Activities Ref.
E. macrorrhiza C.A.Mey.
ex Ledeb. China Roots Hydro-distillation
Acorenone
B (25.80), (+)-cycloisosativene (12.40),
β-cedrene (7.98), copaene (6.29),
3β-hydroxy-5α-androstane (5.52)
Cytotoxic activity against Caco-2
cell line (IC50 = 11.86 µg/mL),
antibacterial activity against
Staphyloccocus aureus (MIC =
2.8 µg/mL) but lower than
ampicillin (MIC = 0.25 µg/mL)
[71]
E. pekinensis Rupr. China Roots Steam distillation Agarospirol (49.23), hedycargol (20.66) not evaluated [72]
E. pilosa L. India Aerial parts Hydro-distillation Phytol (5.75), n-pentadecanal (5.12) not evaluated [73]
E. rigida M.Bieb. Greece Inflorescences Steam distillation
Heneicosane (13.8), heptacosane (12.7),
β-caryophyllene (9.4), linalool (6.7),
pentacosane (6.5)
not evaluated [59]
E. sanctae-caterinae
Fayed Egypt Aerial parts Hydro-distillation
Valencene (16.01), (+)
spathulenol (15.41), (-)-caryophyllene
oxide (10.50), limonene (7.66)
not evaluated [74]
E. sanctae-caterinae
Fayed Egypt Aerial parts Microwave-assisted
Butyl hydroxyl toluene (25.58),
β-eudesmol (13.67),
6-epi-shyobunol (11.83), (+)
spathulenol (10.32), thymol (7.00)
not evaluated [74]
E. teheranica Boiss. Iran Aerial parts Hydro-distillation Elemol (57.5), β-caryophyllene (8.1%),caryophyllene oxide (7.8%) not evaluated [75]
E. thymifolia L. India Aerial parts Steam distillation Palmitic acid (33.03), phytol (10.367),myristic acid (6.58) not evaluated [76]
E. tithymaloides L. Bangladesh Aerial parts Steam distillation
Eugenol (22.52), phenyl ethyl
alcohol (14.63), 3-pentanol (9.22),
caryophyllene oxide (7.73),
isoeugenol (7.32), pentadecanol (5.14),
spathulenol (5.11)
Radical scavenging
activity (DPPH IC50 =
13.67 µg/mL) higher than
BHA (IC50 = 18.26 µg/mL).
[77]
a Compounds with content higher than 5%.
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The Table 1 data show that EOs were obtained mainly from aerial parts (39%) and inflorescences
(29%), in addition to leaves (18%), roots (11%), and stems (3%), by using basically two extraction
methods—hydro-distillation (HD) (52%) and steam distillation (SD) (45%). The oil yield ranged from
0.07% to 1.52% (w/v) in E. cotinifolia (syn. E. caracasana) and E. fischeriana, and from 0.08% to 0.84% (w/w)
in E. pilosa and E. densa. Microwave-assisted extraction (MAE) was reported only once (3%) with faster
extraction time (3:1) and higher oil yield (1.2% vs. 0.7% w/v) than conventional techniques (MAE vs.
HD) [74]. Qualitative and quantitative analyses were performed by gas chromatography (GC) or GC
coupled to mass spectrometry (GC-MS). Samples were found to contain from 8 to 83 phytochemicals
representing 81.7–99.9% of the oils content. Oxygenated sesquiterpenes (up to 86.1% of the oil in
E. teheranica) characterize EOs of Euphorbia species, followed by sesquiterpene hydrocarbons (up to
34.8% in E. helioscopia) (Table 1). In general, β-caryophyllene was the most ubiquitous sesquiterpene
present in 50% of the species investigated namely in E. acanthothamnos, E. apios, E. cotinifolia, E.
densa, E. fischeriana, E. fragifera, E. golondrina, E. helioscopia, E. heterophylla, E. rigida, E. sanctae-caterinae,
E. teheranica and E. tithymaloides constituting more than 7% of their EOs (Table 1; Figure 1).
As reported by Lokar et al. [63], different habitats can influence the quantitative composition of
EO from the same species. For example, EO of E. fragifera growing in a xeric habitat was richer in
aromatic terpenes than that obtained from plants collected in shady and moist soils (e.g., 61.55% vs.
3.36% of carvacrol) being the last ones characterized by great quantity of acyclic compounds (e.g.,
1.24% vs. 59.65% of geraniol). Moreover, variation in the components of EOs may occur due to the
season, geographical area, and date of collection [63].
From Table 1, it appears that most of the EOs of Euphorbia species studied exhibit antioxidant
properties, especially by the radical scavenging mechanism. Note that some of them are more active
than ascorbic acid, BHT, or BHA compounds well known for their antioxidant properties and are
widely used in the food industry as a preservative.
On the other hand, the data presented also show that there are many Euphorbia species whose EOs
are still not yet studied, thus evidencing a knowledge gap about the potential of these species.
4. Antibacterial and Antifungal Activity of Euphorbia Plants
Plants belonging to the genus Euphorbia are also of the great interest in the matter of their
antimicrobial activity [51,52,78–80]. In fact, these plants are also widely used in the traditional medicine
in the microbial infections [81,82], and some Euphorbia plants are believed to be a promising source
of phytochemicals used in the pharmacy and food industries [83]. Since consumers prefer healthy
products without synthetic raw materials, the constantly growing interest in the natural and ecologically
friendly antimicrobial agents is still being observed, and therefore research on the antimicrobial activity
involving Euphorbia species is relevant. The most recent studies in this subject and with greater impact
is summarized in Table 2. This is not an exhaustive list of all studies performed, and only those that
meet as a minimum requirement the indication of at least one statistical parameter associated with the
average value of activity level (e.g., standard deviation) are included.
According to Ashraf et al. [84], the hexane extract of E. royleana, when compared with methanol
and water extracts, is the one with highest phenolic and flavonoid contents and the best antimicrobial
agent. In fact, it exhibits antifungal activity against Aspergillus niger and antibacterial activity against
the gram-positive bacteria Bacillus subtilis, about half that of the reference compounds (rifampicin
and terbinafine).
Biomolecules 2019, 9, 337 10 of 22
Table 2. Antibacterial and antifungal activity of Euphorbia extracts.
Euphorbia Species Tested Extract Activity against Highest Level ofActivity * Ref.
E. royleana Boiss.
Water
Methanol
Hexane
Escherichia coli, Bacillus
subtilis, Pasteurella multocida,
Aspergillus niger,
Fusarium solani
Hexane extract
against A. niger
14.00 ± 1.00 mm
(terbinafine:
25.66 ± 1.69 mm)
[84]
E. hirta L.
E. tirucalli L.
E. neriifolia L.
Methanol
Pseudomonas aeruginosa,
Staphylococcus aureus,
Bacillus subtilis, Escherichia
coli, Cryptococcus luteolus,
Candida albicans, Candida
tropicalis, Candida neoformans
Extract of
E. tirucalli against P.
aeruginosa 14.00 ±
0.00 mm.
[85]
E. neriifolia L.
Chloroform
Ethanol
Ethyl acetate
Butanol
Water
Staphylococcus aureus,
Klebsiella pneumonia,
Escherichia coli,
Proteus vulgaris,
Pseudomonas fluorescents
Chloroform extract
against P. vulgaris 8
± 0.4 mm.
[86]
E. paralias L. AcetoneChloroform
Salmonella enterica,
Escherichia coli, Bacillus
subtilis, Pseudomonas
aeruginosa, Staphylococcus
aureus, Candida albicans
Chloroform extract
against B. subtilis
MIC = MBC =
15 µg/mL
(Gentamicin, MBC
= 15 µg/mL)
[87]
E. granulata Forssk.
E. helioscopia L.
E hirta L.
Ethanol
Klebsiella pneumonia, Proteus
vulgaris, Streptococcus
pyogenes, Escherichia coli,
Staphylococcus aureus,
Staphylococcus epidermidis,
Geotrichum candidum,
Microsporum canis,
Trichophyton mentagrophytes,
Aspergillus fumigatus,
Candida albicans,
Candida tropicalis
Extract of E. hirta
against S. aureus
and M. canis MIC
1.95 µg/mL
(ampicillin MIC =
0.06 µg/mL;
amphotericin B
MIC = 1.95 µg/mL)
[88]
E. hirta L. Ethanol
Escherichia coli,
Staphylococcus aureus,
Pseudomonas aeruginosa,
Bacillus subtilis
Against S. aureus
MIC =
22.55 mg/mL
[89]
E. hirta L.
Hexane
Dichloromethane
Ethyl acetate
Ethanol
Enterobacter aerogenes,
Escherichia coli, Klebsiella
pneumonia, Proteus mirabilis,
Proteus vulgaris, Pseudomonas
aeruginosa, Salmonella typhi,
Shigella dysenteriae,
Staphylococcus aureus,
Bacillus subtilis
Ethanol extract
against S. typhi
MIC= 31 µg/mL
(chloramphenicol
MIC = 62 µg/mL)
[90]
E. characias L. EthanolWater
Staphylococcus aureus,
Bacillus cereus, Listeria
monocytogenes, Escherichia
coli, Salmonella typhimurium,
Candida albicans,
Saccharomyces cerevisiae,
Aspergillus flavus,
Penicillium chrysogenum
Ethanol extract
against B. cereus
MIC = 312.5 µg/mL
(ampicillin MIC =
10 µg/mL)
[91]
* Express as diameter of inhibition zone (mm), as minimum inhibitory concentration, MIC or as minimum bactericidal
concentration (MBC) (µg/mL). When available, the antimicrobial activity of the reference compound is presented.
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The methanol extracts of E. hirta L. and E. tirucalli L. exhibit similar activity against a broad
spectrum of bacteria and fungi associated with skin infections (zones of growth inhibition ranged from
9.0 mm (B. subtilis) to 14.0 mm (P. aeruginosa)) [85]. These results support the use of these species in
traditional Indian medicine, and they can be used as an easily accessible source of natural antimicrobial
agents [85].
The results obtained by Kumara Swamy et al. [86] showed that, independent of the extract
prepared and the microorganism tested, E. neriifolia exhibits low antibacterial and antifungal activity,
being the less interesting Euphorbia species as a source of antimicrobial agents.
In another study, the chloroform extract of E. paralias L. stems seems to be the most interesting
extract, since it exhibits similar activity against fungi, gram-positive, and gram-negative bacteria (MIC
= 15 µg/mL against C. albicans, B. subtilis, and E. coli strains, Table 2), while the chloroform extract
of leaves only exhibits identical activity against C. albicans. The acetone extracts exhibit low activity
against all the microorganisms tested [87].
According to the study conducted by Awaad et al. [88], the ethanolic extract of E. hirta aerial
parts was the most active against all the bacteria and fungi tested when compared with E. granulata
and E. helioscopia ethanol extracts, exhibiting an antifungal activity against M. canis similar to the
amphotericin B in the same experimental conditions. Moreover, the authors demonstrated that
heptacosan-1-ol, isolated from the active extract, could be the main metabolite responsible to the
antimicrobial activity of E. hirta extract.
The study conducted by Ogbulie et al. [89] revealed that ethanolic extracts of E. hirta leaves
showed higher activity against the gram-positive bacteria S. aureus (MIC = 22.55 mg/mL) than against
the other microorganisms tested, but it was much less active than the ethanol extract of aerial parts
against the same S. aureus strain (MIC= 1.95 µg/mL).
Unlike the ethanolic extract from the leaves of E. hirta, that does not inhibit the growth of Salmonella
typhi, the ethanolic extract of aerial part from this species used in the study of Perumal et al. [90] that
exhibited the strongest antimicrobial activity against Salmonella typhi with MIC value of 31 µg/mL,
an activity higher than the chloramphenicol activity against the same strain (Table 2). Additionally,
the same extract (the ethanolic extract of aerial part) also exhibits, against the gram-negative bacteria
Proteus vulgaris, higher activity (MIC = 250 µg/mL) than the reference compounds gentamicin and
chloramphenicol (MIC = 500 µg/mL) [90]. On the other hand, hexane extract was not active against all
the tested microorganisms, except a weak activity against P. vulgaris [90].
Pisano et al. [91] carried out relatively extensive studies on the antimicrobial activity of the
aqueous and ethanolic extracts from leaves, stems, and flowers of E. characias L. (Table 2). The results
showed that most of these extracts are non-active against the organisms tested (MIC > 1.25 mg/mL),
with the exception of the ethanolic extract from leaves against gram-positive bacteria Bacillus subtilis
(MIC = 312.5 µg/mL).
5. Other Biological Activity of Euphorbia Plants
The Euphorbia plants have been used as medicinal plants for the treatment of many human
ailments besides to those caused by bacteria and fungi. In fact, as will be demonstrated in the items
below, Euphorbia extract and compounds have been evaluated as potential natural drugs with many
other activities such as anti-inflammatory, antiviral, and antitumour.
5.1. In Vitro Studies
Studies on in vitro biological activity of several Euphorbia plants have been reported, involving
both extracts and pure compounds.
The cytotoxicity of the crude extract of the stem bark of E. umbellata (Pax) Bruyns and its fractions
(hexane, chloroform, ethanol, and methanol) were studied using in vitro assay and by applying the
leukemic cells Jurkat clone E6-1 [92]. The study revealed that the CHCl3 fraction had the highest
cytotoxicity (IC50 = 7.72 µg/mL), an activity value much lower than the reference compound vincristine
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(IC50 = 0.0031 µg/mL), but below the limit 30 µg/mL. According to NCI criteria [93], the activity of
extracts is considered interesting to be studied in more detail. The established mechanism responsible
for this action was associated with the promotion of cell cycle arrest at G0/G1 phase and apoptosis,
which was related to two main classes of compounds in this fraction—steroids and triterpenes [92].
More recently, ethanolic extract of latex from E. umbellata has been evaluated for its anti-HIV
properties. The study demonstrated in several models (in resting CD4+T cells, in cells from HIV-1 +
individuals, and in primary non-human primate CD4+T cells) that this extract is able to reactivate the
HIV virus in latency, acting on three factors with synergistic effect [94].
The ethanolic extract of E. lunulata Bunge (this name is a synonym of E. esula L.), at 10–20 µg/mL,
had a significant anti-proliferative, anti-migration, and anti-invasion effect on multidrug resistant
human gastric SGC7901/ADR cells, being able to arrest cell cycle progression and to induce cell
apoptosis [95]. The same study further revealed that the cell cycle was arrested in G2/M phase, while
significant apoptotic morphological changes was observed.
Methanolic extract of E. hirta aerial parts exhibited 90% growth inhibition against Plasmodium
falciparum at 5 µg/mL and low toxicity against KB 3-1 cells, demonstrating its potential as antimalarial
agent [96]. From this extract and by a bio-guided methodology, the authors isolated three flavonol
glycosides—afzelin, quercitrin, and myricitrin (Figure 2)—that exhibit the ability to significantly inhibit
the proliferation of the protozoan responsible for malaria disease Plasmodium falciparum strains FCR-3
(cycloguanil-resistant from Gambia) and CDC1 (chloroquine sensitive), with similar IC50 values 2.5 to
11.6 µM [96]. Quercitrin is able to arrest irreversibly the life cycle of the parasite at the trophozoite
stage [96].
Several diterpenes isolated from stem bark of E. neriifolia exhibit anti-HIV-I activity [97]. Among
these diterpenes, euphorneroid D and ent-3-oxoatisan-16α,17-acetonide (Figure 2) were the most active
compounds, with EC50 values of 34 µM and 24 µM respectively, although much less active than the
reference compound (zidovudine, EC50 = 0.0019 µM). Besides these diterpenes, the ingenol derivative
EK-16A (Figure 2), isolated from the E. kansui S.L.Liou ex S.B.Ho, can also be useful as antiviral agent
against HIV-1 [98]. In fact, this compound is a PKCγ activator, 200-fold more potent (IC50 = 3.53 to
4.06 nM) than prostratin (IC50 = 768 to 865 nM) in reactivating latent HIV-1 without exerting detectable
cytotoxicity on C11 and the J-Lat 10.6 cells viability and T cell activation. In addition, this compound
exhibits a synergistic effect with other activators of HIV-1 from latency like prostratin, 5-azacytidine,
and romidepsin [98].
The seeds of E. lathyris contain many natural macrocyclic diterpenes with a lathyrane
skeleton [46,99], five of which were evaluated against A549, MDA-MB-231, MCF-7, KB, and KB-VIN
cancer cell lines [99]. The compound EFL-9 (Figure 2) exhibits the strongest cytotoxicity against all
cell lines (IC50 values ranging from 5.7 to 8.4 µM against four of the five cell lines tested). The most
important is its similar toxicity against the multidrug-resistant cancer cell line KB-VIN and the parental
cell KB line (IC50 values of 5.7 and 6.1 µM, respectively), while the anticancer taxol exhibits a highly
differentiated toxicity to these cell lines (IC50 values of 1.9 µM and 6.7 nM, respectively) [99]. The
nicotinate ester at C-7 on the EFL-9 compound seems to play a crucial role in the cytotoxicity against
the KB-VIN cell line. Additionally, the cytotoxicity of EFL-9 is due to its action on actin filament
aggregation as well as on partial disruption of microtubules networks [99].
Biomolecules 2019, 9, 337 13 of 22
Biomolecules 2019, 9, 337 11 of 20 
 
Figure 2. Chemical structures of in vitro bioactive Euphorbia compounds. 
Several diterpenes isolated from stem bark of E. neriifolia exhibit anti-HIV-I activity [97]. Among 
these diterpenes, euphorneroid D and ent-3-oxoatisan-16α,17-acetonide (Figure 2) were the most 
active compounds, with EC50 values of 34 μM and 24 μM respectively, although much less active 
than the reference compound (zidovudine, EC50 = 0.0019 μM). Besides these diterpenes, the ingenol 
derivative EK-16A (Figure 2), isolated from the E. kansui S.L.Liou ex S.B.Ho, can also be useful as 
antiviral agent against HIV-1 [98]. In fact, this compound is a PKCγ activator, 200-fold more potent 
(IC50 = 3.53 to 4.06 nM) than prostratin (IC50 = 768 to 865 nM) in reactivating latent HIV-1 without 
exerting detectable cytotoxicity on C11 and the J-Lat 10.6 cells viability and T cell activation. In 
addition, this compound exhibits a synergistic effect with other activators of HIV-1 from latency like 
prostratin, 5-azacytidine, and romidepsin [98]. 
The seeds of E. lathyris contain many natural macrocyclic diterpenes with a lathyrane skeleton 
[46,99], five of which were evaluated against A549, MDA-MB-231, MCF-7, KB, and KB-VIN cancer 
cell lines [99]. The compound EFL-9 (Figure 2) exhibits the strongest cytotoxicity against all cell lines 
(IC50 values ranging from 5.7 to 8.4 μM against four of the five cell lines tested). The most important 
Figure 2. Chemical structures of in vitro bioactive Euphorbia compounds.
Helioscopinolide A (Figure 2), one jolkinolide-type diterpenoid isolated from the ethanolic extract
of E. helioscopia whole plant exhibits a strong cytotoxic activity against HeLa cells line (IC50 = 0.11
µM), being even more active than the adriamycin used as positive control (IC50 = 0.41 µM) [100].
Helioscopinolide A exhibits moderate activity against MDA-M -231 cells line (IC50 = 2.1 µM) and is
much lesser active than Ad iamycin (IC50 = 0.34 µM) [100].
According Safwat et al. [101], querce in-3-O-β-d-gluco ide (Figure 2), a safe compound isola ed
from 7 % methanol extract of E. paralias whole plant, in add tion to exhibiting moderate oxicity
against HepG2 and A549 cancer cell lines (IC50 values of 41 and 36 µM, respectively), exhibits the
ability to inhibit the glutamine synthetase enzyme (IC50 = 0.048 µM). Taking into account that this
enzyme is identified as a potential target in the development of new antimycobacterial agents, once it
plays a significant role as virulence factor of Mycobacterium tuberculosis, Safwat et al. [101] showed that
quercetin-3-O-β-d-glucoside could be used as an antituberculotic agent.
Several isolated diterpenoids from the roots of E. ebracteolata Hayata were reported to inhibit human
carboxylesterase 2 (hCE-2), a human enzyme able to metabolize clinical drugs, resulting in adverse
clinical reactions such as the reduction of biological availability of the drugs [102]. The compound
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4αβ,9α,16,20-tetrahydroxy-14(13→12)-abeo-12αH-1,6-tigliadiene-3,13-dione (Figure 2) exhibits the
strongest competitive inhibitory activity (IC50 = 3.88 µM, with Ki = 4.94 µM), a higher activity than the
hCE-2 inhibitor BNNP (IC50 = 5.60 µM). On the other hand, this compound has non-toxic effect against
HCT-116, HepG2, BGC-823, H460, and SK-OV-3 cell lines (IC50 >100 µM) [102], which is an advantage
in its application as an hCE-2 inhibitor.
Helioscopianoid P and helioscopianoid H (Figure 2) are two jatrophane-type diterpenoids isolated
from the whole plants of E. helioscopia, at 20µM, exhibit inhibitory effects on P-glycoprotein in adriamycin
(ADM)-resistant human breast adenocarcinoma cell line (MCF-7/ADR), while helioscopianoid L,
helioscopianoid H and helioscopianoid B (Figure 2), also jatrophane-type diterpenoids isolated from
the same species, exhibit neuroprotective effects against serum deprivation-induced PC12 cell damage
and rotenone-induced PC12 cell damage [103].
The main component of E. umbellata and E. tirucalli latex is the tetracyclic triterpene alcohol euphol
(Figure 2) [104,105]. This compound exhibits cytotoxic effect against several leukemia, colorectal,
melanoma and glioma cancer cell lines [104,105]. When tested against Jurkat, HL-60, K-562 B16F10
and HRT-18 cell lines, euphol is toxic mainly against K-562 cell line (34.44 µM) by apoptosis induction,
with non-toxicity to blood cells (SI > 2), but low selectivity to 3T3 cell line (SI = 0.55) [104]. On the other
hand, euphol is particularly active against glioma cells (including primary, paediatric and adult glioma
cell lines), with IC50 values range from 5.98 to 31.05 µM, much more active than the temozolomide, a
clinical drug used to treat some brain cancers (IC50 values range from 97.00 µM to 1 mM) and with
higher selective cytotoxicity index (0.64–3.36) than temozolomide (0.11–1.13) [105].
5.2. In Vivo Studies
The first significant in vivo studies reported on Euphorbia extracts or pure compounds were
published in the 1990s. For example, the lyophilized E. hirta decoction exhibits antidiarrheal activity
on diarrhoea induced by castor oil, arachidonic acid, and prostaglandin E2, but is inactive when
the diarrhoea is induced by magnesium sulphate [106]. The flavonoid quercitrin (Figure 2) isolated
from the previously reported lyophilized E. hirta decoction, exhibits antidiarrheal activity (at doses of
50 mg/kg), in castor oil- and PGE2-induced diarrhoea in mice [107], although the same authors showed
that quercitrin activity is due to the glycone quercetin released in the intestine [107]. On the other hand,
the water extract of E. hirta leaves, in adult Wister rats at 50–100 mg/kg dose, exhibits diuretic effect
and increase the excretion of Na+, K+ and HCO3 [108].
However, the highest incidence of in vivo studies involving Euphorbia species has occurred in the
last few years.
The 80% hydroethanolic extract of E. tirucalli latex at 0.250 mg (daily for 21 and 35 days) seems
to be able to induce significant increases in TH1 cytokines (GM-CSF, IL-2), TH2 cytokines (IL-6), and
chemokines (IL-1β, RANTES) and thus incite immunological stimulation and improve the immune
system on adult male Sprague Dawley rats [109].
A steroid and terpenoid-rich fractions were isolated from the hydroethanolic extract of E. tirucalli
root that, at 60 mg/kg, exhibits better protection against peripheral nociceptive pain on acetic acid
induced abdominal constrictions mice model than the analgesic aceclofenac sodium and better
anti-inflammatory activity in carrageenan-induced mice model than indomethacin [110].
On the other hand, the 70% hydroethanolic extract of E. supina Raf. (this name is a synonym of
E. maculata L.), at 10 mg/mL, is able to significantly reduce the ear thickness and number of inflammatory
cells on the Propionibacterium acnes-induced skin inflammation by inhibition of pro-inflammatory
cytokines expression and the MAPK signalling pathway [111].
The wound-healing activity of different extracts (n-hexane, ethyl acetate, and methanol) from aerial
parts of different Euphorbia species (E. helioscopia, E. characias subsp. Wulfenii (Hoppe ex W.D.J.Koch)
Radcl.-Sm., E. macroclada Boiss., E. seguieriana subsp. seguieriana (this name is a synonym of E. seguieriana
Neck.), and E. virgata Waldst. & Kit. (this name is a synonym of E. esula subsp. tommasiniana (Bertol.)
Kuzmanov), was evaluated in vivo by Özbilgin et al. [112]. The authors showed that the methanol
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extract of E. characias subsp. wulfenii was the most active, significantly reducing the linear incision
wound (43.04%) while the circular excision wound decreased 65.24%, with a significant decrease in
wound inflammation (34.74%) in relation to the control groups. These activities were further linked
with the quercetin glycosides identified in the extract [113].
A comparative study with several species, including E. helioscopia, E. lactea Haw., and E. nivulia
Buch.-Ham. showed that the ethanol extract from the latter (at 100 mg/kg) was the one that caused
the greatest anticonvulsant effects and highest reduction in the progression of epileptogenesis in
pentylenetetrazole-induced kindling model of epilepsy in mice [114].
It was well demonstrated that the lyophilized decoction of fresh whole E. hirta had great potential
against dengue virus since, after 14 days of administration at 100 mg/kg dose, it significantly increased
platelet counts in rats, also causing a decrease in coagulation time and bleeding [115].
As shown above and in a recent review on the subject [116], several reports have suggested that
Euphorbia plant possesses, in in vitro assays, considerable cytotoxic potential. Some in vivo studies also
corroborate the anticancer potential and safety of Euphorbia extracts and compounds. For example, the
methanolic extract of E. triaculeata Forssk., when tested in albino mice at 250 to 1000mg/kg body weight,
is not genotoxic or clastogenic, while the pre-treatment with this extract inhibits the clastogenicity
induced by cyclophosphamide without impairing its cytotoxic potential [117].
The tetracyclic triterpene alcohol, euphol (Figure 2), showed antitumoural effects in GAMG glioma
model through the activation of autophagy-associated cell death [105].
Euphornin L (Figure 3), a relatively abundant jatrophane diterpenoid from E. helioscopia, exhibits
outstanding lipid-lowering effect on golden Syrian hamsters fed with a high-fat diet at a well-tolerated
dose of 30mg/kg (p.o.) [118]. In fact, the authors observed a significant decrease on CHOL and LDL-C
levels in the treatment group when compared with control group, while other parameters (HDLC, TG,
and body weight) did not suffer significant changes [119].
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Euphorbia f ctor L2 (EFL-2, Figure 3), a seco lite isolated from seeds of E. lathyris,
was te ted to treat lipo lysaccharide (LPS) induce i jury (ALI) in mice [119]. EFL-2 at
con e tration f 40 mg/kg causes an atte ua ion of the pa ological changes in the lung by significant
suppression of the recruitment and trans igration of inflammatory cells, specifically neutrophils [119].
The same compound was tested, using SMMC7721 xenograft BALB/c nude mice, to evaluate its effect
on human hepatocellular carcinoma [120]. EFL-2, administered at 25 and 50 mg/kg for 14 days, is able
to inhibit the growth of hepatocellular carcinoma in BALB/c athymic nude mice, causing a decrease in
tumour volume and weight, mainly by targeting STAT3 and AKT inactivation during TGF-β-induced
EMT and metastasis [120].
From E. helioscopia aerial parts were isolated several secondary metabolites that exhibit
vasodepressive activity, being the euphornin (Figure 3) the most active, causing a significant reduction
in direct blood pressure (42 mmHg) in an adult male Wistar albino rat model during 70 min [121].
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5.3. Clinical Studies
There are very few clinical studies involving Euphorbia species. In a clinical trial whose results
were published in 2011 [122], skin cancer lesions (basal cell carcinomas, squamous cell carcinomas,
and intraepidermal carcinomas) were treated topically with 100–300 µL of E. peplus latex (daily for
three days). The results showed this latex exhibits a clinical response that is comparable to existing
non-surgical treatments used in clinical therapeutics against human non-melanoma skin cancers. The
active ingredient of E. peplus latex has been identified as ingenol mebutate, the active principle of the
clinical medicine Picato®used in the treatment of actinic keratosis [24].
The E. hirta extract is able to cause an increase in the number of platelets in dengue patients from
30–55 age group and a decrease in flu-like symptoms in 70% of the patients. However, no identical
effect was observed in the 14–25-age group [123].
A clinical study on phase 2 to determine the safe and efficacious dose of E. prostrata for control of
per rectal bleeding in patients with first- and second-degree haemorrhoids is now complete (Clinical
Trials Identifier: NCT01041911) [124]. In that trial, 82% of the patients had complete cessation of
bleeding at the end of two weeks and thus demonstrate that E. prostrata can be used as an effective
therapeutic agent and without adverse effects in the treatment of early stage haemorrhoids [125].
A clinical trial involving E. kansui (an E. kansui extract powder prepared as tea) is currently in the
recruitment phase and intends to evaluate the immune response of HIV+ individuals to this herbal
supplement and its dependence with the dose applied. Also, the safety of the herbal preparation is
evaluated (Clinical Trial Identifier: NCT02531295) [124].
6. Conclusions
The Euphorbia species are plants well known for their applications, especially its latex, in traditional
medicine around the world. Their chemical composition may vary according to the species, to the part
of the plant, and the applied extraction methodology. This variability could also be influenced by the
different habitats, seasons, and dates of collection. Quantitative and qualitative analysis have been
developed for the compounds’ identification, being the major constituents of essential oils oxygenated
sesquiterpenes followed by sesquiterpene hydrocarbons.
Additionally, several studies reported and discussed above, confirmed, in vitro, in vivo, and in
clinical trials, the biological activities of Euphorbia extracts and pure compounds. These compounds and
extracts could be applied to the treatment of different diseases mainly related to microbial infections,
as well as inflammation and cancer.
Euphorbia plants have great potential as a source of bioactive extracts and pure compounds, which
may lead to the development of new drugs for clinical use.
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